Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 20, 2026, 4:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 33 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Non Cystic Fibrosis Bronchiectasis Clear all
Recruiting Phase 2 Interventional

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Adult Study Participants With Non-Cystic Fibrosis Bronchiectasis

NCT07720375
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Galvokimig, Placebo
Biological
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Brandon, Florida • Plantation, Florida • DuBois, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01314716
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
274 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
33
States / cities
Florence, Alabama • Flagstaff, Arizona • Peoria, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 20, 2026, 4:54 AM EDT
Recruiting Phase 2 Interventional

A Phase II Study of Ensifentrine in Non-Cystic Fibrosis Bronchiectasis

NCT06559150
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Nebulized Ensifentrine Suspension; 3 mg, Nebulized Placebo Solution
Drug
Lead sponsor
Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Industry
Eligibility
18 Years to 80 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
29
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 20, 2026, 4:54 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis

NCT05006573
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Benralizumab, Placebo to Benralizumab
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
4
States / cities
Birmingham, Alabama • Newport Beach, California • Northridge, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

NCT05616221
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis, Pseudomonas Aeruginosa, Lung Infection
Interventions
AP-PA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Farmington, Connecticut + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Safety and Effectiveness of AZLI (an Inhaled Antibiotic) in Adults With Non-Cystic Fibrosis Bronchiectasis

NCT01313624
View directory record Official record
Conditions
Bronchiectasis
Interventions
AZLI, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
36
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT03218917
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mg, Brensocatib 25 mg, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
18 Years to 85 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Peoria, Arizona • Newport Beach, California + 30 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2023 · Synced Sep 20, 2026, 4:54 AM EDT
Suspended Phase 2 Interventional

A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

NCT07547436
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
SAR445399, Placebo
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Phoenix, Arizona • Loxahatchee Groves, Florida • Plantation, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Not applicable Interventional Results available

Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability

NCT01615484
View directory record Official record
Conditions
Emphysema, Chronic Obstructive Pulmonary Disease (COPD), Cystic Fibrosis, Pulmonary Fibrosis, Bronchiectasis, Sarcoidosis, Pulmonary Hypertension, Alpha-1 Antitrypsin Deficiency
Interventions
Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™, STEEN Solution™
Procedure · Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
15 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 7, 2018 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 3 Interventional

Phase 3 Study With Ciprofloxacin Dispersion for Inhalation in Non-CF Bronchiectasis (ORBIT-4)

NCT02104245
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin dispersion for inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years and older
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2021 · Synced Sep 20, 2026, 4:54 AM EDT
Recruiting No phase listed Observational

Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Muco-Obstructive Lung Disease

NCT06985225
View directory record Official record
Conditions
Severe Asthma, COPD, Non-CF Bronchiectasis, Cystic Fibrosis (CF)
Interventions
Hyperpolarized 129 Xenon
Combination Product
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Sep 20, 2026, 4:54 AM EDT
Terminated Phase 3 Interventional Results available

Trial in Non-cystic Fibrosis Bronchiectasis Patients With Chronic Lung Infections Treated With Colistimethate Sodium.

NCT03460704
View directory record Official record
Conditions
Non Cystic Fibrosis Bronchiectasis
Interventions
CMS, Placebo
Drug · Other
Lead sponsor
Zambon SpA
Industry
Eligibility
18 Years and older
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Newport Beach, California • Palm Springs, California • Reseda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 20, 2026, 4:54 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Regional Phenotyping of CF and Non-CF Bronchiectasis

NCT04793867
View directory record Official record
Conditions
Cystic Fibrosis, Non-CF Bronchiectasis
Interventions
Xenon
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Sep 20, 2026, 4:54 AM EDT
Terminated Not applicable Interventional

A Pilot Study to Evaluate the Use of the Vest® System for Treatment of Bronchiectasis Patients in the Home Setting

NCT04017312
View directory record Official record
Conditions
Bronchiectasis, Bronchiectasis With Acute Exacerbation
Interventions
High Frequency Chest Wall Oscillation, Oscillating Positive Expiratory Pressure (OPEP)
Device
Lead sponsor
Hill-Rom
Industry
Eligibility
18 Years to 80 Years
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
New York, New York • Nashville, Tennessee • Tyler, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2024 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 1 Interventional

Safety and Potential Efficacy of Human Mesenchymal Stem Cells in Non-Cystic Fibrosis Bronchiectasis

NCT02625246
View directory record Official record
Conditions
Bronchiectasis
Interventions
hMSCs
Biological
Lead sponsor
Marilyn Glassberg
Other
Eligibility
30 Years to 87 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Ciprofloxacin Dry Powder for Inhalation in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

NCT01764841
View directory record Official record
Conditions
Bronchiectasis
Interventions
Ciprofloxacin DPI (BAYQ3939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
39
States / cities
Jasper, Alabama • Flagstaff, Arizona • Phoenix, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

Ciprofloxacin Dry Powder for Inhalation (DPI) in Non-cystic Fibrosis Bronchiectasis (Non-CF BE)

NCT02106832
View directory record Official record
Conditions
Bronchiectasis
Interventions
Ciprofloxacin (BAYQ3939) dry powder for inhalation, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
22
States / cities
Peoria, Arizona • Fountain Valley, California • La Jolla, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cipro Inhale in Patients With Non-cystic Fibrosis Bronchiectasis

NCT00930982
View directory record Official record
Conditions
Bronchiectasis
Interventions
Ciprofloxacin (Cipro, BAYQ3939), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Little Rock, Arkansas • La Jolla, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2014 · Synced Sep 20, 2026, 4:54 AM EDT
Recruiting Phase 4 Interventional

Hypertonic Saline in NCFB

NCT06242795
View directory record Official record
Conditions
Bronchiectasis, Non-cystic Fibrosis Bronchiectasis
Interventions
7% Hypertonic Saline via nebulization
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 20, 2026, 4:54 AM EDT
Recruiting Not applicable Interventional

Breathing Training and Exercise Capacity in Non-CFB

NCT05860803
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
LungTrainers, LungTrainers Pulmonary Rehabilitation regime
Device · Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 80 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis

NCT04594369
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Brensocatib 10 mg, Brensocatib 25 mg, Placebo
Drug
Lead sponsor
Insmed Incorporated
Industry
Eligibility
12 Years to 85 Years
Enrollment
1,767 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
67
States / cities
Birmingham, Alabama • Conway, Arkansas • Little Rock, Arkansas + 61 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 4 Interventional

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

NCT05743946
View directory record Official record
Conditions
Non-cystic Fibrosis Bronchiectasis
Interventions
Trikafta
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

A Proof-of-Concept Study to Assess the Efficacy, Safety and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Non-cystic Fibrosis Bronchiectasis

NCT06280391
View directory record Official record
Conditions
Bronchiectasis
Interventions
Itepekimab (SAR440340), Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 85 Years
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
32
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Sep 20, 2026, 4:54 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy Study of Ciprofloxacin for Inhalation in Patients With Non-Cystic Fibrosis Bronchiectasis "ORBIT-1"

NCT00889967
View directory record Official record
Conditions
Non-Cystic Fibrosis Bronchiectasis
Interventions
Ciprofloxacin for Inhalation, Placebo
Drug
Lead sponsor
Aradigm Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
14
States / cities
Phoenix, Arizona • Los Angeles, California • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Sep 20, 2026, 4:54 AM EDT